Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline/Day 1 (prior to first dose of study drug)~* Have a PASI score of 12 or greater AND a PGA score of 3 (moderate) or 4 (severe) at Baseline/Day 1 (prior to first dose of study drug)~* Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at Baseline/Day 1 (prior to first dose of study drug)~* Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment)~Exclusion Criteria:~* Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed~* Have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis~* Cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA)~* Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).~* Have taken Apremilast (Otezla) within 3 months of first dose of study drug.~* Have undergone treatment with tofacitinib within 3 months of first dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06700841 60 mg followed by 30 mg once daily (Type: EXPERIMENTAL): 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
- PF-06700841 60 mg followed by 10 mg once daily (Type: EXPERIMENTAL): 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
- PF-06700841 60mg once daily followed by 100mg once weekly (Type: EXPERIMENTAL): 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
- PF-06700841 60mg once daily followed by placebo once daily (Type: EXPERIMENTAL): 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
- PF-06700841 30mg once daily (Type: EXPERIMENTAL): 4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
- PF-06700841 30mg once daily followed by 10mg once daily (Type: EXPERIMENTAL): 4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
- PF-06700841 30mg once daily followed by 100mg once weekly (Type: EXPERIMENTAL): 4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
- Placebo (Type: PLACEBO_COMPARATOR): 12 weeks once daily placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete